AB0411 IMPACT OF GENDER IN JAK INHIBITORS PRESCRIPTION: ANALYSIS FROM A SINGLE CENTER COHORT
Authors: E. Grau García, J. J. Fragío Gil, R. González Mazarío, P. Muñoz Martinez, L. Mas Sanchez, C. Pávez Perales, S. Leal Rodriguez, A. V. Huaylla Quispe, C. Riesco Barcena, M. De la Rubia Navarro, F. Ortiz-Sanjuán, I. Martínez Cordellat, J. E. Oller Rodríguez, R. Negueroles Albuixech, J. Ivorra Cortés, L. Gonzalez Puig, E. Vicens Bernabeu, I. Cánovas Olmos, C. Nájera Herranz, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2022)

Background Gender differences in demographic and clinical features may have a direct impact in patient prognosis. Objectives We aimed to investigate gender differences in disease manifestations, comorbidities and treatment among patients who had started treatment with Janus Kinase Inhibitors. Methods A single center observational study was performed including patients who had initiated treatment with Tofacitinib, Baricitinib or Upadacitinib from September, 2017 to January, 2022. Demographic and clinical data was collected and subgroup analysis was performed. Results A total of 190 patients were included (84%) and their characteristics are exposed in Table 1. Discontinuation rate was 33% in men and 39% in women. In female patients, age of diagnosis was younger (p=0.04) and the disease evolution, longer (p&lt;0.01). Rheumatoid Arthritis was more frequent in women and Psoriatic Arthritis in men. Smoking habit was more seen in females (p&lt;0.01). High Blood Pressure and Diabetes Mellitus were more frequent in men but dyslipidemia was more seen in women with no statistical signification. Men were more likely to receive a JAKi in first indication (p&lt;0.02). At the time of first dose of JAKi, DAS28 and SDAI were similar between both sexes but HAQ was higher in women. All the laboratory markers (CRP, ESR, RF and ACPA) were higher in women than in men. Table 1. POPULATION CHARACTERISTICS. Men group n=30 (16%) Women n=160 (84%) Age – years (ds) 55.73 (14.66) 53.57 (17.29) Age at diagnosis 46.93 (15.64) 39.9 (15.71) Disease evolution (years) 10.73 (7.04) 16.79 (11.88) Rheumatoid Arthritis 21 (70%) 139 (86.88%) Psoriatic Arthritits 6 (20%) 11 (6.88%) Juvenile Idiopathic Arthritis 1 (3.33%) 6 (3.75%) Other 2 (6.67%) 4 (2.5%) Baricitinib 3 (10%) 59 (36.88%) Tofacitinib 22 (73.33%) 81 (50.62%) Upadacitinib 5 (16.67%) 20 (12.5%) Race – number (%) Caucasian 24 (88.89%) 137 (86.16%) Latin 3 (11.11%) 21 (13.21%) Other 0 (0%) 1 (0.63%) Smokers – number (%) 3 (17.65%) 30 (27.03%) Mean glucocorticoid dosage – mg of prednisone or equivalent 2.85 (3.37) 4.53 (4.24) Comorbidities – number (%) 10 (33.33%) 39 (24.38%) High blood pressure 3 (10%) 11 (6.88%) Diabetes Mellitus 7 (23.33%) 53 (33.12%) Dyslipidemia Fibromyalgia 0 (0%) 6 (5.45%) Prior bDMARD– number (%) Naïve patients 17 (60.71%) 55 (34.59%) 1 bDMARD failure 2 (7.14%) 33 (20.62%) 2 bDMARD failure 3 (10.71%) 21 (13.12%) 3 or more bDMARD failure 6 (21.43%) 45 (28.12%) DAS 28 – mean total score 5.01 (1.13) 5.02 (0.98) SDAI – mean total score 22.31 (8.43) 25.21 (9.24) HAQ – median total score 1.38 (0.91, 1.5) 1.62 (1.25, 1.88) CRP – mg/L 5 (3.02, 11) 7 (2, 18.9) ESR – mm/h 16 (8, 32) 29.5 (17, 49.5) Rheumatoid Factor 16 (10, 166) 37 (10, 169.5) ACPA 138 (0.7, 340) 204.5 (1.08, 340) Conclusion In this analysis of 190 patients treated with JAKi we detect that the men uses JAKi more frequently in first indication than women. Women seems to have a longer disease evolution, more smoking habit and less cardiovascular risk than men. Disclosure of Interests None declared